ArticleCase reports in nephrology and dialysis
Fibronectin Glomerulopathy: A First African Case Report.
Article in Case reports in nephrology and dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fibronectin glomerulopathy is a rare autosomal dominant disorder characterized by abnormal deposition of fibronectin within the kidney. It is associated with several variant mutations in the FN1 gene. It is a disorder predominantly characterized by proteinuria that can reach the nephrotic range, and it has been primarily described in Asian and White populations. Here, we report a case of fibronectin glomerulopathy from Ethiopia, which, to our knowledge, is the first ever reported in Africa. Case Presentation: A 17-year-old Ethiopian female presented with generalized body swelling and nephrotic range proteinuria. Secondary causes of nephrotic syndrome were ruled out, but kidney biopsy was not performed early because of financial constraints. The patient received initial treatments with RASi (renin-angiotensin system inhibitor) and diuretics followed by steroids and tacrolimus, but lacked a clear response. Eventually, a kidney biopsy and examination at a pathology laboratory in India revealed extensive periodic acid Schiff-positive but Jones' methenamine silver-negative and Congo red-negative mesangial and capillary wall deposits, which stained strongly for fibronectin on immunohistochemistry. A diagnosis of fibronectin glomerulopathy was made. Conclusion: Diagnosing fibronectin glomerulopathy could be challenging in many developing nations due to a lack of proper pathological and genetic testing infrastructure. Improving local health infrastructure for kidney tissue diagnosis could improve diagnostic accuracy, better guide management, and help avoid the administration of unnecessary medications with a potential for serious adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.